Amartya Pal

Mr. Amartya Pal

Pathology, Stony Brook University, Stony Brook, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAmartya Pal
Amartya Pal
AOAnushka Ojha
Anushka Ojha
JJJingfang Ju
Jingfang Ju
The alarmingly low five-year survival rate for pancreatic cancer presents a global health challenge, contributing to about 7% of all cancer-related deaths. Late-stage diagnosis and high heterogeneity are the biggest hurdles in treating pancreatic cancer. Thus, there is a pressing need to discover novel biomarkers that could help in early detection as well as improve therapeutic strategies. MicroRNAs (miRNAs), a class of short non-coding RNA, have emerged as promising candidates with regard to both diagnostics and therapeutics. Dysregulated miRNAs play pivotal roles in accelerating tumor growth and metastasis, orchestrating tumor microenvironment, and conferring chemoresistance in pancreatic cancer. The differential expression profiles of miRNAs in pancreatic cancer could be utilized to explore novel therapeutic strategies. In this review, we also covered studies on recent advancements in various miRNA-based therapeutics such as restoring miRNAs with a tumor-suppressive function, suppressing miRNA with an oncogenic function, and combination with chemotherapeutic drugs. Despite several challenges in terms of specificity and targeted delivery, miRNA-based therapies hold the potential to revolutionize the treatment of pancreatic cancer by simultaneously targeting multiple signaling pathways.

29 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AOAnushka Ojha
Anushka Ojha
APAmartya Pal
Amartya Pal
MCMax Chao
Max Chao
Ramana DavuluriRamana Davuluri
Ramana Davuluri
JJJingfang Ju
Jingfang Ju
Background: Resistance to 5-fluorouracil (5-FU)-based chemotherapy is a major clinical obstacle in colorectal cancer (CRC), highlighting the urgent need to overcome established resistance mechanisms. MicroRNA-based therapeutics have emerged as compelling candidates in this context, given their inherently pleiotropic mode of action; however, their clinical translation remains hindered by poor stability and suboptimal delivery. Methods: To address these limitations, Gem-miR-15a, a unique gemcitabine-modified tumor-suppressor microRNA-15a was designed to synergistically integrate the tumor-suppressive activity of miR-15a with the chemotherapeutic potency of gemcitabine into a single molecular entity. Therapeutic efficacy of Gem-miR-15a was evaluated across a spectrum of preclinical models, including parental and drug-resistant CRC cell lines, 3D tumor spheroids, patient-derived organoids and in vivo metastatic models. Cell viability, apoptosis and cell cycle analyses were performed, along with RNA sequencing and protein validation. Statistical analyses were conducted using Student’s t-test or two-way ANOVA with mixed effects, and data were presented as mean ± SD. Results: Gem-miR-15a exhibited potent anti-proliferative activity with IC 50 values in the low nanomolar range, achieving ∼100-5000-fold greater potency relative to 5-FU and oxaliplatin. Importantly, it retained efficacy in both 5-FU- and oxaliplatin-resistant CRC models, effectively overcoming acquired chemoresistance. Mechanistically, Gem-miR-15a induced S-phase cell cycle arrest, eliminated the G2-phase cell population, and triggered apoptosis, accompanied by suppression of key oncogenic targets including WEE1, CHK1, YAP1 and BMI1. RNA-seq analysis further demonstrated modulation of pathways such as p53 signaling and reversal of resistance-associated gene expression, that were corroborated at the protein level. In vivo , Gem-miR-15a significantly reduced tumor growth at a dose ∼12-fold lower than gemcitabine, with no observable toxicity. Conclusion: Gem-miR-15a represents a potent, multi-targeted therapeutic strategy capable of overcoming chemoresistance in CRC. Its enhanced stability, effective delivery and robust efficacy across resistant models and a favorable safety profile highlight its strong potential for clinical translation. Graphical

10 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
APAmartya Pal
Amartya Pal
AOAnushka Ojha
Anushka Ojha
JYJohn Yuen
John Yuen
HBHersh Bendale
Hersh Bendale
LCLei Chen
Lei Chen
JJJingfang Ju
Jingfang Ju
Gemcitabine remains a mainstay of pancreatic ductal adenocarcinoma (PDAC) treatment, while the RAS(ON) inhibitor daraxonrasib has recently demonstrated improved survival in previously treated metastatic disease. However, acquired resistance to both therapies remains a major clinical challenge. Here, we developed MTX-5-FU-Gem-miR-15a, a multimodal microRNA (miRNA)-based therapeutic, by chemically modifying tumor-suppressive miR-15a with methotrexate (MTX), 5-fluorouracil (5-FU), and gemcitabine (Gem) to combine sequence specific gene regulation with disruption of nucleotide metabolism. MTX-5-FU-Gem-miR-15a exhibited low-nanomolar potency across five PDAC cell lines and retained activity in gemcitabine- and daraxonrasib-resistant models under vehicle-free conditions, substantially exceeding that of stoichiometrically matched free antimetabolites. Treatment induced S-phase accumulation, increased DNA damage and apoptosis, and suppressed checkpoint and survival-associated proteins, including WEE1, CHK1, YAP1, and BCL-2. Transcriptomic and proteomic analyses revealed increased DNA replication, replication-stress, and repair-associated programs, together with reduced oncogenic signaling. In gemcitabine-resistant cells, treatment restored the gemcitabine-activating enzyme dCK, reduced ABCC1 and ABCC3 expression, and suppressed resistance-associated signaling programs, indicating partial remodeling of resistance-associated pathways. MTX-5-FU-Gem-miR-15a also synergized with daraxonrasib (mean Bliss synergy score, 22.52) and activated tumor-cell-intrinsic STING-TBK1 signaling, accompanied by increased interferon stimulated gene expression and IFN-β and CXCL10 secretion. Finally, MTX-5-FU-Gem-miR-15a retained low-nanomolar potency in three patient-derived PDAC organoids and significantly suppressed metastatic tumor growth in vivo at 4 mg/kg. Together, these findings support a multimodal miRNA therapeutic strategy that combines replication-associated DNA damage, checkpoint protein suppression, and innate immune activation-associated responses to target therapeutic resistance in PDAC.

22 April 2026 in bioRxiv
Verified
Preprint
Open access
APAmartya Pal
Amartya Pal
AOAnushka Ojha
Anushka Ojha
HBHersh Bendale
Hersh Bendale
LCLei Chen
Lei Chen
IOIwao Ojima
Iwao Ojima
JJJingfang Ju
Jingfang Ju
SUMMARY: Epithelial ovarian cancer (EOC) is characterized by high relapse rates and the development of drug resistance, driven by adaptive DNA repair and survival pathways. Here, we develop a multimodal, chemically engineered miRNA therapeutic, MTX-5-FU-Gem-miR-15a, that integrates tumor-suppressive miR-15a activity with chemotherapeutic modifications and tumor-targeting capability. This modified miRNA exhibits potent nanomolar activity across diverse EOC models, including PARP inhibitor-resistant cells, without requiring delivery vehicles. Mechanistically, MTX-5-FU-Gem-miR-15a induces replication stress while suppressing G2/M checkpoint regulators (WEE1 and CHK1), resulting in genomic instability and apoptotic cell death. Transcriptomic and protein-level analyses revealed coordinated suppression of resistance-associated and oncogenic signaling pathways, alongside activation of DNA damage coupled with checkpoint abrogation and potential innate immune response. MTX-5-FU-Gem-miR-15a also demonstrates strong synergy with olaparib and robust antitumor efficacy in vivo . These findings establish a multimodal miRNA-based therapeutic strategy that targets replication stress and checkpoint dependency to overcome PARPi resistance in ovarian cancer.